What is the prevalence of Acute lymphocytic leukemia (ALL)?

Acute lymphocytic leukemia (ALL) is a rare cancer of the blood and bone marrow, with an annual incidence of approximately 1 to 2 cases per 100,000 individuals in the United States and Europe. While it is the most common childhood cancer, it is considered a rare disease in the general population, with prevalence figures reflecting both new diagnoses and those currently living with the condition.

What is the incidence and prevalence of Acute lymphocytic leukemia (ALL)?

The incidence of Acute lymphocytic leukemia (ALL) is approximately 6,000 new cases per year in the United States according to the National Cancer Institute. Because Acute lymphocytic leukemia (ALL) is an aggressive, acute malignancy, prevalence—the total number of people living with the disease at one time—is closely tied to survival rates, which have improved significantly with modern chemotherapy and targeted treatments. It is important to note that global prevalence data can be difficult to aggregate due to variations in healthcare infrastructure and diagnostic capabilities in different regions.

Who is most commonly affected by Acute lymphocytic leukemia (ALL)?

Acute lymphocytic leukemia (ALL) exhibits a bimodal age distribution, meaning it peaks at two distinct stages of life:

• Pediatric: The highest incidence occurs in children between the ages of 2 and 5 years.


• Adult: A second, smaller peak in incidence occurs in adults over the age of 50.


• Gender: Data consistently shows a slight male predominance, with males being diagnosed with Acute lymphocytic leukemia (ALL) at a rate approximately 20% higher than females.

Are there geographic or ethnic variations in the occurrence of the disease?

Epidemiological studies indicate that Acute lymphocytic leukemia (ALL) is more frequently diagnosed in Hispanic children compared to other ethnic groups in the United States. While the exact causes of these variations remain under investigation, researchers believe a combination of genetic susceptibility and environmental factors likely plays a role in the development of Acute lymphocytic leukemia (ALL).

What does the DiseaseMaps.org community data show?

Currently, 9 individuals with Acute lymphocytic leukemia (ALL) have joined the DiseaseMaps.org community to share their lived experiences. While this is a small sample, it provides a vital, real-world perspective on the patient journey that complements clinical statistics, offering insights into the daily challenges of managing this condition.

Next steps

• Consult an oncologist or hematologist specializing in leukemia to discuss personalized treatment plans.


• Visit the Leukemia & Lymphoma Society (LLS) for patient support resources and clinical trial matching.


• Join the DiseaseMaps.org community to connect with others navigating a diagnosis of Acute lymphocytic leukemia (ALL).

Medical disclaimer: This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment; always seek the advice of your physician regarding a medical condition.

References

• National Cancer Institute (NCI) - Surveillance, Epidemiology, and End Results (SEER) Program.


• NIH Genetic and Rare Diseases (GARD) Information Center.


• Orphanet: Portal for rare diseases and orphan drugs.


• The Leukemia & Lymphoma Society (LLS) - Facts and Statistics.